SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending strongly following reports that a former US President is instructing representatives to buy $200 billion in mortgage bonds, a move expected to significantly lower mortgage rates and enhance housing affordability. The community is highly optimistic, anticipating a substantial surge in the housing market and a potential short squeeze, with many celebrating this development as a major catalyst for the company's prospects.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as its innovative Optical Interposer technology gains significant validation, notably following Marvell's acquisition of partner Celestial AI, underscoring its pivotal role in next-generation AI and data center optical interconnects. The community is buzzing about POET's patented, high-speed, and energy-efficient solutions, which are critical for scaling AI infrastructure beyond copper's limitations. Speculation is high for major upcoming orders and a substantial revenue ramp, positioning the company as a key player in the photonics sector.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto is gaining significant attention as its dedicated "Wolfpack" community rallies around the recent launch of WolfSwap, a cross-chain aggregator, and eagerly anticipates a groundbreaking flagship utility. The community remains highly bullish, driven by continuous building and a vision to usher in a new era for memecoins, emphasizing decentralized growth and utility.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies (RKT) is trending following news of former President Trump's plans to stimulate the housing market, including instructing representatives to buy $200 billion in mortgage bonds and potentially banning institutional home purchases. This has ignited community discussion around an impending refinance boom and increased housing affordability, positioning RKT's integrated mortgage and real estate platform for a significant re-rating and potential new highs. Investors are actively debating the magnitude of this positive catalyst on RKT's business model.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a high-profile social media post from former President Trump, praising the company's CEO, government investment, and new sub-2nm CPU processor. This has fueled widespread community discussion around Intel's renewed technological competitiveness with its 18A process and Core Ultra Series 3 chips for AI PCs, driving optimism for a significant turnaround despite some skepticism about sustained momentum.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is attracting significant attention following its update on triple-digit growth for its AI back pain platform, robust cash position, and no debt. The community is buzzing about the extremely low float and potential for a massive short squeeze, drawing comparisons to $SMX. However, some traders voice concerns over perceived market manipulation attempting to suppress the price, despite the strong underlying fundamentals.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following recent preliminary financial guidance that prompted significant community concern over DefenCath's future revenue, particularly regarding the anticipated end of TDAPA. While many investors express frustration and question management's strategy, others contend the sell-off is an overreaction, highlighting potential legislative support and recent positive real-world evidence for DefenCath's efficacy to reassure long-term value.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is attracting significant attention as the market keenly awaits congressional decisions on extending Affordable Care Act (ACA) subsidies, following a House-passed bill and ongoing bipartisan Senate negotiations for a potential extension. Community discussion is polarized, with many anticipating a substantial rally and potential short squeeze given the high short interest if an extension is secured, while skeptics foresee further downside if an agreement falters. Adding to the volatility, recent analyst upgrades suggest confidence in the company's long-term profitability and market positioning, independent of the immediate subsidy outcome.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association (FNMA) is trending amidst heightened speculation about its future, fueled by recent commentary from prominent figures regarding potential government-directed mortgage bond purchases and its substantial cash reserves. The community is actively discussing these developments as signals for the long-anticipated privatization, including a potential uplisting or IPO, which could significantly impact the housing market and mortgage rates. Noted investors are also expressing bullish sentiment, further intensifying the conversation around the mortgage giant's path out of conservatorship.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Down 29.4% in December

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 220,276 shares...

Gregg Williams Acquires 1,737,765 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 1,737,765 shares of Vivani Medical stock in a transaction that occurred on Monday, December 15th. The shares were...

FY2025 EPS Estimates for Vivani Medical Boosted by Analyst

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Vivani Medical in a research report issued on...

Vivani Medical (NASDAQ:VANI) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen raised Vivani Medical to a "sell" rating in a research report on Saturday...

Gregg Williams Purchases 1,737,764 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,737,764 shares of Vivani Medical stock in a transaction on Saturday, November 15th. The stock was purchased at...

Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,737,764 Shares

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 1,737,764 shares of Vivani Medical stock in a transaction dated Saturday, November 15th. The shares were bought...

Vivani Medical (NASDAQ:VANI) Upgraded to Hold at Zacks Research

Zacks Research raised shares of Vivani Medical from a "strong sell" rating to a "hold" rating in a report on Wednesday...

Vivani Medical (NASDAQ:VANI) Issues Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12...

Vivani Medical (VANI) Projected to Post Earnings on Wednesday

Vivani Medical (NASDAQ:VANI) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...

Vivani Medical, Inc. (VANI), on Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vivani.com/investors/news-events/press-releases/detail/188/vivani-medical-announces-positive-preclinical-weight-loss">announced</a> promising preclinical data for its semaglutide implant in development for weight management in overweight patients.NPM-139 is a small, subdermal semaglutide implant. Semaglutide is the active ingredient in popular weight-loss drugs such as Ozempic or Wegovy.Vivani Medical CEO Adam Mendelsohn said products containing semaglutide generated $25 billion in 2024, and demand for these products continues to soar.“Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes,” he said.The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.NPM-139 is being initially developed as a twice-yearly implant but has the potential benefit of once-yearly administration, the company said.The company also said it recently successfully implanted an initial group of human subjects with NPM-115, a miniature, ultra long-acting exenatide implant aimed at overweight persons.Data from the study of NPM-115 is expected to be available mid-2025. The study is also expected to pave the way for the development of NPM-139, the company said.On Stocktwits, retail sentiment about Vivani rose from ‘bullish’ to ‘extremely bullish’ territory while message volume jumped from ‘low’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:649/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_26_at_1_56_56_PM_png_deb5769989.webp" alt="VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits" width="649" height="150"><figcaption>VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits commended the company’s idea of implants, taking out the need for daily pills or injections.<stembedurl>https://stocktwits.com/ZabDad/message/609254484</stembedurl>Brokerage H.C. Wainwright said on Wednesday that the preclinical data validates the versatility of the company’s proprietary NanoPortal implant technology while reiterating a ‘Buy’ rating on the shares with a price target of $4.A Stocktwits user, however, highlighted the company’s low cash. As of Sept. 30, 2024, Vivani had cash, cash equivalents, and restricted cash totaling $21 million.<stembedurl>https://stocktwits.com/Earl40/message/609298832</stembedurl><a href="https://stocktwits.com/symbol/VANI">VANI shares</a> traded nearly 2% higher on Wednesday afternoon. The stock is down over 6% this year and by over 40% in the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-spins-off-micromobility-business-into-new-company-also/chJbT8iRb3m">Rivian Spins Off Micromobility Business Into New Company ‘Also’: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A tape measure lies on a scale while a young woman buries her head in her hands in the background. (Photo by Pia Bayer/picture alliance via Getty Images)

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant. 

Equity

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

Vivani Medical Inc

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

Current Price	$1.31
Prev Close	$1.29
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.41
Beta	0.60
Avg. Volume	210,906.55
PE Ratio	-2.92

52-Week High	$1.92
52-Week Low	$0.9054
Market Capitalization	$94.11M
EPS (Annual)	-$0.4272
Price to Book	60.62
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VANI
Vivani Medical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VANI News

VANIVivani Medical Inc